AACR 2023: CRB-601, an αvβ8 blocking antibody, prevents activation of TGFβ and exhibits anti-tumor activity associated with immune cell remodeling of the tumor microenvironment
CRB-601, a selective integrin avβ8 blocking antibody, exhibits potent anti-tumor activity in anti-PD-1 resistant models
58th European Association for the Study of Diabetes (EASD) presentation on CRB-913 (CB1 Inverse Agonist)
